Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Urogen Pharma (NASDAQ:URGN – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
Profitability
This table compares Gyre Therapeutics and Urogen Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
| Urogen Pharma | -51.73% | N/A | -43.79% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Gyre Therapeutics and Urogen Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
Institutional & Insider Ownership
24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Gyre Therapeutics and Urogen Pharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gyre Therapeutics | $116.59 million | 7.22 | $5.03 million | ($0.21) | -35.95 |
| Urogen Pharma | $109.79 million | 19.26 | -$153.49 million | ($1.98) | -21.84 |
Gyre Therapeutics has higher revenue and earnings than Urogen Pharma. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Gyre Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Summary
Gyre Therapeutics beats Urogen Pharma on 8 of the 14 factors compared between the two stocks.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
